To View SHC 2024 Videos and Download PDF Slides:

Prof. Jia Jidong

Prof. Jidong Jia is currently Professor of Medicine, Director of Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China. Professor Jia is the immediate past President of the International Association for the Study of the Liver(IASL), past President of Asian Pacific Association for the Study of the Liver (APASL 2009-2010) and Chinese Society of Hepatology (CSH 2006-2012). Professor Jia also serves as Associate Editor for Hepatology International and served as Associate Editor for Journal of Gastroenterology & Hepatology and Liver International. As a hepatologist, his clinical interests include viral, cholestatic/autoimmune and genetic liver diseases. His research work focuses mainly on cellular and molecular biology of the extracellular matrix of the liver and the pathogenesis and therapeutic study of experimental liver fibrosis. In addition, Dr. Jia has been PI or sub-PI for many clinical trials and also heavily engaged in the teaching of clinical research methodology for residents and fellows in clinical medicine. He has authored or co-authored more than one hundred papers published in national and international journals including Gastroenterology, Gut, Hepatology, and Journal of Hepatology.

Prof. Harry Janssen

Prof. Harry Janssen is a Professor of the Department of Gastroenterology and Hepatology at Erasmus MC, Rotterdam, The Netherlands.

Prof. Janssen has led numerous international multicenter clinical and translational studies on the natural history and treatment for chronic viral hepatitis and other liver diseases. His clinical and translational research aiming for immunological control and cure of hepatitis B and C has led to several globally used novel treatment concepts. He is currently the most cited global expert in chronic hepatitis B (Expertscape nr 1 among 28.932 scientists). His research contributions include sustained federal funding (greater than 20 years), over 600 peer reviewed publications, an H-index of 115, and over 60,000 citations (Google Scholar). He has acquired over $50 million USD in research funding from many different organizations among which NIH, European Commission, CIHR, NWO and ZonMW.

Dr. Chee Cheng Ean

Dr. Chee Cheng Ean graduated from the University College London (UCL) Medical School, London, UK with a Bachelor of Science (Hons) in Tumour Biology in 2001 and MBBS (Lond) in 2004. She then pursued her post-graduate training in the US by completing her residency in Internal Medicine (2008) and fellowship in Haematology and Oncology (2011) at the Mayo Clinic in Rochester, Minnesota. She was also appointed as Chief Fellow of the Mayo Clinic Haematology/Oncology Fellowship Program and promoted to Assistant Professor of Medicine and Oncology during her time at Mayo Clinic. Dr Chee subsequently joined the Division of Haematology/Oncology at Case Western Reserve University in Cleveland, Ohio, USA as an attending physician and Assistant Professor of Medicine.

Her clinical research portfolio includes a novel biomarker study in colorectal cancer which was awarded institutional and national grant funding. She also developed and was Principal Investigator and national study chair of a Phase I/II US cooperative group clinical trial of a Wee1 inhibitor in pancreas cancer which received full support and endorsement by the Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging Network (ACRIN) and Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) in the US. Her work in pancreas cancer lead to her appointment as the ECOG representative to the Pancreatic Cancer Task Force of the NCI Gastrointestinal Steering Committee. She has many publications in peer-reviewed journals and has been invited as a journal reviewer in her field.

Dr. Chee is a specialist in medical oncology and currently practices as a senior consultant medical oncologist and clinician scientist, and also holds the Deputy Director (Clinical) position at the National University Cancer Institute, Singapore. She is board certified by the American Board of Internal Medicine (ABIM) in Internal Medicine, Medical Oncology and Haematology.

Dr. Chee’s interests are in cancers of the gastrointestinal (GI) tract which includes colorectal cancer, liver and pancreas cancers, cancers of the biliary tract, stomach and oesophageal cancers. She is also interested in drug development of novel agents and phase I trials.